Characteristics of R&D expenditures in Japan's pharmaceutical industry
Characterized by a high level of R&D expenditure, pharmaceutical firms are also subject to specific risks that are reflected in their financial policies. In contrast to other firms, whose investments are directly related to internal cash flows, Japanese pharmaceutical companies do not appear to rely on this source of funds to undertake R&D investments. Our analysis reveals that R&D expenses largely depend on the firm's size and the strength of its balance sheet. More precisely, high levels of debt appear to hold back R&D expenditure, especially when debt has a short-term maturity. These results highlight the importance of funding risky investments with the adequate type of capital to avoid putting firms in financial distress. Despite the risk, R&D investments seem to be justified by the fact that they are generally associated with higher sales growth. However, the difficult conditions prevailing in Japan's pharmaceutical industry make these benefits less visible.
Year of publication: |
2012
|
---|---|
Authors: | Nivoix, Sophie ; Nguyen, Pascal |
Published in: |
Asia Pacific Business Review. - Taylor & Francis Journals, ISSN 1360-2381. - Vol. 18.2012, 2, p. 225-240
|
Publisher: |
Taylor & Francis Journals |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
The effect of group affiliation on the risk-taking of Japanese firms
Nguyen, Pascal, (2009)
-
The valuation of R&D expenditures in Japan
Nguyen, Pascal, (2010)
-
Characteristics of R&D expenditures in Japan's pharmaceutical industry
Nivoix, Sophie, (2012)
- More ...